Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
Open Access
- 25 May 2018
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 36 (8) , 1015-1027
Abstract
Objective To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic therapy (biologic-experienced population). Perspective and Setting UK National Health Service (NHS). Methods The model was structured as a 3-month decision tree leading into a Markov model. Comparators were licensed tumour necrosis factor inhibitors (including available biosimilars) and CC in the biologic-naïve and biologic-experienced populations, respectively. Clinical parameters captured treatment response, short-term disease activity and patient functioning, as well as long-term structural disease progression. Utilities were derived from secukinumab trial data. List prices were used for all drugs. The cost year was 2017 and costs and outcomes were discounted at 3.5%. Results In the biologic-naïve population, secukinumab dominated adalimumab and certolizumab pegol. Incremental cost-effectiveness ratios (ICERs) versus other comparators were either below £10,000 per quality-adjusted life-year (QALY) gained or south-west ICERs that implied cost effectiveness of secukinumab. In biologic-experienced patients, the ICER for secukinumab versus CC was £4927 per QALY gained. Treatment response rates, short-term treatment effects, long-term radiographic progression and biologic acquisition costs were key model drivers. Scenario analysis found results to be robust to changes in model structural assumptions. Probabilistic analysis identified greater uncertainty in results in the biologic-naïve population. Conclusions Even at list price, secukinumab appears to represent a cost-effective use of NHS resources for biologic-naïve and biologic-experienced patients with active AS. Further research on long-term radiographic progression outcomes would be valuable for future cost-effectiveness analyses in AS.Keywords
Funding Information
- Novartis Pharmaceuticals UK Limited
This publication has 15 references indexed in Scilit:
- BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologicsRheumatology, 2016
- Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluationHealth Technology Assessment, 2016
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisNew England Journal of Medicine, 2015
- Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect MethodsValue in Health, 2015
- Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS studyAnnals of the Rheumatic Diseases, 2015
- The Impact of Tumor Necrosis Factor α Inhibitors on Radiographic Progression in Ankylosing SpondylitisArthritis & Rheumatism, 2013
- Increased mortality in ankylosing spondylitis is related to disease activityAnnals of the Rheumatic Diseases, 2011
- Adverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database of Systematic Reviews, 2011
- Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spineAnnals of the Rheumatic Diseases, 2009
- Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: A game of two halves?International Journal of Technology Assessment in Health Care, 2008